The ratio of (statistical) risk in the intervention group to the risk in the control group. A RR of one indicates no difference between comparison groups. For undesirable outcomes an RR that is less than one indicates that the intervention was effective in reducing the risk of that outcome.
R
Relugolix (Orgovyx®). HTA ID: 23017
| Assessment Status | Rapid Review Complete |
| HTA ID | 23017 |
| Drug | Relugolix |
| Brand | Orgovyx® |
| Indication | Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. |
| Assessment Process | |
| Rapid review commissioned | 14/03/2023 |
| Rapid review completed | 31/03/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that relugolix not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations January 2024.
Rozanolixizumab (Rystiggo®). HTA ID: 26023
| Assessment Status | Rapid Review Complete |
| HTA ID | 26023 |
| Drug | Rozanolixizumab |
| Brand | Rystiggo® |
| Indication | Rozanolixizumab (Rystiggo®) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |
| Assessment Process | |
| Rapid review commissioned | 13/05/2026 |
| Rapid review completed | 28/05/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rozanolixizumab compared with the current standard of care. |